• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Chem Biodivers . Computational screening of neuropilin 1 unveils novel potential anti-SARS-CoV-2 therapeutics

tetano

Editor, Senior Moderator
Chem Biodivers


. 2023 Oct 25:e202301227.
doi: 10.1002/cbdv.202301227. Online ahead of print. Computational screening of neuropilin 1 unveils novel potential anti-SARS-CoV-2 therapeutics

Michael Afiadenyo[SUP] 1 [/SUP], Latif Adams[SUP] 2 [/SUP], Clement Agoni[SUP] 3 [/SUP], Siobhan Moane[SUP] 4 [/SUP], Michelle McKeon-Bennett[SUP] 4 [/SUP], Dorcas Obiri-Yeboah[SUP] 5 [/SUP], Jasdeep Singh[SUP] 6 [/SUP]



Affiliations
Abstract

Neuropilin 1 (NRP-1) inhibition has shown promise in reducing the infectivity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and preventing the virus entry into nerve tissues, thereby mitigating neurological symptoms in COVID-19 patients. In this study, we employed virtual screening, including molecular docking, Molecular Dynamics (MD) simulation, and Molecular Mechanics-Poisson Boltzmann Surface Area (MM-PBSA) calculations, to identify potential NRP-1 inhibitors. From a compendium of 1930 drug-like natural compounds, we identified five potential leads: CNP0435132, CNP0435311, CNP0424372, CNP0429647, and CNP0427474, displaying robust binding energies of -8.2,-8.1,-10.7,-8.2, and -8.2 kcal/mol, respectively. These compounds demonstrated interactions with critical residues Tyr297, Trp301, Thr316, Asp320, Ser346, Thr349, and Tyr353 located within the b1 subdomain of NRP-1. Furthermore, MD simulations and MM-PBSA calculations affirmed the stability of the complexes formed, with average root mean square deviation, radius of gyration, and solvent accessible surface area values of 0.118 nm,1.516 nmand 88.667nm² respectively. Notably, these lead compounds were estimated to penetrate the blood-brain barrier and displayed antiviral properties, with Pa values ranging from 0.414 to 0.779. The antagonistic effects of these lead compounds merit further investigation, as they hold the potential to serve as foundational scaffolds for the development of innovative therapeutics aimed at reducing the neuroinfectivity of SARS-CoV-2.

Keywords: C-end Rule * molecular docking * molecular dynamics simulation * neuropilin-1 * SARS-CoV-2.

 
Back
Top Bottom